CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0002960: AutoimmunityHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)


Name (Synonyms) Correlation
drug1981 Questionnaire by phone call Wiki 0.58
drug473 COVID-19 diagnostic test Wiki 0.58
drug471 COVID-19 convalescent hyperimmune plasma Wiki 0.58
drug1634 Non-convalescent fresh frozen plasma (Standard plasma) Wiki 0.58
drug560 Chloroquine Wiki 0.20
drug1853 Placebo oral tablet Wiki 0.11

Correlated MeSH Terms (13)


Name (Synonyms) Correlation
D001327 Autoimmune Diseases NIH 1.00
D012859 Sjogren's Syndrome NIH 0.82
D025241 Spondylarthritis NIH 0.58
D008180 Lupus Erythematosus, Systemic NIH 0.47
D001167 Arteritis NIH 0.41
D012213 Rheumatic Fever NIH 0.41
D001168 Arthritis NIH 0.33
D011111 Polymyalgia Rheumatica NIH 0.33
D013700 Giant Cell Arteritis NIH 0.33
D003095 Collagen Diseases NIH 0.29
D015535 Arthritis, Psoriatic NIH 0.29
D012216 Rheumatic Diseases NIH 0.26
D001172 Arthritis, Rheumatoid NIH 0.22

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0002725 Systemic lupus erythematosus HPO 0.47
HP:0012089 Arteritis HPO 0.41
HP:0001369 Arthritis HPO 0.33
HP:0001370 Rheumatoid arthritis HPO 0.22

There are 3 clinical trials

Clinical Trials


1 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

NCT04345159 SARS-CoV-2 Systemic Lupus Erythematosus Rheumatoid Arthritis Sjogren's Syndrome Psoriatic Arthritis Other: Questionnaire by phone call
MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.

Measure: Adjusted Odds Ratio

Time: 4 months after inclusion

2 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study

Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases
MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity

Primary Outcomes

Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death

Time: From Baseline up to Day 21 after first symptoms of covid-19

Secondary Outcomes

Measure: Proportion of patients who die from a severe form of covid-19

Time: From Baseline up to Day 21 after first symptoms of covid-19

Measure: Proportion of patients who present an history of diabetes according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2)

Time: At the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Asthma according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Hypertension according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cardiac disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of stroke according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cancer according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

3 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

NCT04397237 COVID-19 Systemic Lupus Erythematosus Sjogren's Syndrome Axial Spondyloarthritis Rheumatoid Arthritis Giant Cell Arteritis
MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

Primary Outcomes

Description: ELISA tests for COVID-19 antibodies

Measure: COVID-19 seroconversion

Time: 1 day, during routine blood collection

Description: Case report form filled by the health professional

Measure: COVID-19 infection

Time: During medical visit or phone consultation, up to 2 hours

Secondary Outcomes

Description: Descriptive analysis for each disease's rate

Measure: Seroconversion rate by disease

Time: 1 day, during routine blood collection

Description: Descriptive analysis for each country's rate

Measure: Penetration across Europe

Time: 1 day, during routine blood collection

Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

Measure: COVID-19 severity

Time: During medical visit, up to 1 hour

Description: Descriptive analysis for overall and COVID-19-linked mortality rates

Measure: COVID-19 mortality rate

Time: During contact with family members, up to 1 hour

Description: Case report form filled by the health professional

Measure: COVID-19 impact on immunomodulatory treatment

Time: During medical visit, up to 1 hour

Description: Case report form filled by the patient

Measure: Patient-reported flares

Time: During medical visit, up to 1 hour

Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

Measure: Patient's fears towards COVID-19

Time: During medical visit, up to 1 hour

Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

Measure: Patient's beliefs in their medicines towards COVID-19

Time: During medical visit, up to 1 hour


HPO Nodes